Translation inhibitors induce cell death by multiple mechanisms and Mcl-1 reduction is only a minor contributor

LM Lindqvist; I Vikstroem; JM Chambers; K McArthur; M Ann Anderson; KJ Henley; L Happo; L Cluse; RW Johnstone; AW Roberts; BT Kile; BA Croker; CJ Burns; MA Rizzacasa; A Strasser; DCS Huang

Journal article

Translation inhibitors induce cell death by multiple mechanisms and Mcl-1 reduction is only a minor contributor

LM Lindqvist, I Vikstroem, JM Chambers, K McArthur, M Ann Anderson, KJ Henley, L Happo, L Cluse, RW Johnstone, AW Roberts, BT Kile, BA Croker, CJ Burns, MA Rizzacasa, A Strasser, DCS Huang

Cell Death & Disease | NATURE PUBLISHING GROUP | Published : 2012

DOI: 10.1038/cddis.2012.149

University of Melbourne Researchers

Christopher Burns Author Chemistry

Mark Rizzacasa Author Chemistry

David Huang Author Medical Biology (W.E.H.I.)

Ricky Johnstone Author The Sir Peter MacCallum Department of Oncology

Andreas Strasser Author Medical Biology (W.E.H.I.)

Related Projects (3)

2007 Program Grant - (Immune Regulation, Effector Function And Human Immunotherapy)

The immune system plays an important role in protecting the host from viral and bacterial infections, and inhibits cancer onset and progress..

2007 Program Grant - (Immune Regulation, Effector Function And Human Immunotherapy)

The immune system plays an important role in protecting the host from viral and bacterial infections, and inhibits cancer onset and progress..

Defining The Apoptotic And Therapeutic Activities Of Histone Deacetylase Inhibitors

HDAC inhibitors (HDACi) are new chemotherapeutic drugs that kill tumors cells through a cell suicide process called apoptosis. We have used ..

Grants

Awarded by Independent Research Institutes Infrastructure Support Scheme IRIISS

Awarded by Leukemia and Lymphoma Society (SCOR)

Funding Acknowledgements

We thank Drs K Mason, D Segal and D Vaux for insightful discussions; SL Khaw for sharing results pre-publication; D Tarlinton, C Scott, P Bouillet, D Green, S Korsmeyer, N Motoyama and C Thompson for gifts of reagents including mice; Abbott for ABT-737; H Donatucci and G Siliciano for animal husbandry; A Georgiou, H Ierino, A Srikumar, C Clarke, R Lindeman and K Stanley for technical support. Our laboratories are supported by fellowships and grants from the Australian National Health and Medical Research Council (Early Career Fellowship to LML; Research Fellowships to RWJ, AWR (honorary), BTK, DCSH; Australia Fellowship to AS; program grants 461219, 461221, 1016701 to RWJ, AWR, BTK, AS and DCSH, 461221, 454569 to RWJ, project grants 637360 to DCSH, 637367 to BAC, 637326 to AS, 1028871 to RWJ; Independent Research Institutes Infrastructure Support Scheme IRIISS grant 361646), Australian Research Council (Fellowship to BAC; Discovery Grant to MAR), Victorian Cancer Agency (Clinical Research Fellowship to AWR), the Leukemia and Lymphoma Society (SCOR grant 7413), the Canadian Institutes of Health Research (Postdoctoral Fellowship to LML, who is also a Bisby Fellow), Cancer Therapeutics CRC (JMC, MAR), Jill and Ross Webster Bequest (scholarship to MAA), Susan G Komen Breast Cancer Foundation (RWJ), Cancer Council of Victoria (RWJ), Leukemia Foundation of Australia (RWJ), Victorian Breast Cancer Research Consortium (RWJ), Victorian Cancer Agency (Clinical Research Fellowship to AWR; RWJ) and a Victorian State Government Operational Infrastructure Support (OIS) grant.